Author(s): Baez A; Hazel K; Guertin Z; Fong E; Manus MM; Kaloyannis A; Helfield B;

Adoptive cell transfer (ACT)-based immunotherapy has emerged as a transformative approach for treating cancer, offering durable responses through the ex vivo expansion and reinfusion of antigen-specific immune cells. Despite remarkable clinical successes, most notably with chimeric antigen receptor (CAR)-T cell therapy, ACT remains limited by severe toxic ...

Article GUID: 41748028

Author(s): McComb S; Arbabi-Ghahroudi M; Hay KA; Keller BA; Faulkes S; Rutherford M; Nguyen T; Shepherd A; Wu C; Marcil A; Aubry A; Hussack G; Pinto DM; Ryan S; Raphael S; van Faassen H; Zafer A; Zhu Q; Maclean S; Chattopadhyay A; Gurnani K; Gilber ...

Chimeric antigen receptor (CAR) T cell therapies targeting B cell-restricted antigens CD19, CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but relapse remains common. Camelid single-domain antibodies (sdAbs or nanobodies) are smaller, simpler, and easier to reco ...

Article GUID: 38596311